Introduction
The hepatocyte growth factor receptor (HGFR), also known as c-Met or mesenchymal - epithelial transition factor (Met), has emerged as a receptor tyrosine kinase (RTK) of great significance in both normal physiological processes and the development of various diseases. Its discovery and subsequent research have opened new avenues for understanding cellular mechanisms and developing targeted therapies. This comprehensive review aims to explore the structure, function, signaling pathways, and clinical implications of HGFR.
Structure of HGFR
The MET gene, located on human chromosome 7, spans approximately 125 kb of DNA and consists of 21 exons and 20 introns. It encodes the c-Met protein, which is a heterodimer linked by disulfide bonds. Structurally, c-Met can be divided into two main parts: extracellular and intracellular domains. The extracellular part contains a SEMA domain, a PSI domain, and four consecutive IPT1 - 4 domains. These extracellular domains play crucial roles in ligand binding and receptor dimerization. The intracellular domain is composed of a juxtamembrane domain, a tyrosine kinase domain, and a C - terminal multifunctional docking site. The tyrosine kinase domain is responsible for the catalytic activity of the receptor, while the C - terminal docking site recruits various signaling molecules upon receptor activation.
Physiological Functions of HGFR
Embryonic Development and Organogenesis
During embryonic development, HGFR - mediated signaling is essential for organogenesis and tissue morphogenesis. It contributes significantly to the formation and development of multiple organs. For example, in liver development, HGFR signaling promotes hepatocyte proliferation, migration, and differentiation. In the kidney, it is involved in the formation of the renal tubules. In the lung, HGFR signaling plays a role in branching morphogenesis, which is crucial for the proper development of the respiratory system. In the placenta, it helps in trophoblast invasion and placental angiogenesis, ensuring proper nutrient and oxygen supply to the developing fetus.
Cell Motility and Invasion
Activation of the HGFR promotes cell motility and invasion, which are vital for many physiological functions. In the context of embryonic development, cell motility and invasion are necessary for the proper migration of cells to their correct positions to form tissues and organs. In adults, immune cell migration to sites of inflammation or injury is also regulated in part by HGFR signaling. For instance, macrophages and neutrophils can be guided to the site of tissue damage through HGFR - mediated chemotaxis, facilitating the immune response and subsequent tissue repair.
Angiogenesis and Tissue Repair
HGFR signaling is a key regulator of angiogenesis, the process of new blood vessel formation. In response to tissue injury or damage, HGFR activation stimulates endothelial cell proliferation, migration, and tube formation. This is essential for tissue regeneration and repair. For example, in wound healing, HGFR signaling promotes the growth of new blood vessels into the wounded area, providing oxygen and nutrients to support the proliferation and migration of fibroblasts and keratinocytes, which are crucial for the formation of new tissue.
HGFR Signaling Pathways
Activation by Ligand Binding
The only known ligand for HGFR is hepatocyte growth factor (HGF). When HGF binds to HGFR, it induces receptor dimerization through a mechanism that is not yet fully understood. This dimerization leads to autophosphorylation of specific tyrosine residues within the intracellular domain of HGFR. In particular, tyrosine residues Tyr1234 and Tyr1235 are phosphorylated, which then serve as docking sites for various signal transducers.
Downstream Signaling Cascades
Ras/MAPK Pathway: The Ras pathway is activated upon HGFR phosphorylation. This pathway mediates HGF - induced scattering and proliferation signals, ultimately leading to branching morphogenesis. Notably, unlike most mitogens, HGF induces sustained Ras activation, which in turn prolongs mitogen - activated protein kinase (MAPK) activity. The activation of the Ras/MAPK pathway is crucial for cell growth, proliferation, and differentiation.
PI3K/AKT Pathway: Phosphatidylinositol 3 - kinase (PI3K) can be activated in two ways. It can be located downstream of the Ras pathway or recruited directly through the multifunctional docking site on HGFR. Activation of the PI3K pathway is associated with cell motility, mainly through remodeling of the cell's adhesion to the extracellular matrix and local recruitment of transducers involved in cytoskeletal reorganization, such as Rac1 and p21 - activated kinase (PAK). In addition, activation of the PI3K pathway triggers a survival signal through the activation of the AKT pathway, which helps cells resist apoptosis.
JAK/STAT Pathway: HGFR activation can also lead to the activation of the Janus kinase (JAK)/signal transducer and activator of transcription (STAT) pathway. In particular, Met directly activates the STAT3 transcription factor via its SH2 domain. The activation of the STAT pathway, along with sustained MAPK activation, is required for HGF - induced cladistic morphogenesis.
Wnt/β - catenin Pathway: A key component of the Wnt signaling pathway, β - catenin, translocates into the nucleus after Met activation. Once in the nucleus, β - catenin is involved in the transcriptional regulation of many genes, which can affect cell proliferation, differentiation, and adhesion.
Notch Pathway: The Notch pathway can be activated by the transcription of delta ligands, which can be influenced by HGFR signaling. The Notch pathway plays important roles in cell fate determination, proliferation, and differentiation.
HGFR in Disease
Cancer
Tumor Growth and Progression: Dysregulation of HGFR signaling is a common feature in a wide range of cancers, including lung, breast, gastric, and hepatocellular carcinomas. Aberrant activation of HGFR, often due to gene amplification, mutation, or overexpression, can promote tumor growth. For example, in non - small cell lung cancer (NSCLC), MET exon 14 skipping mutations and MET amplification are important oncogenic drivers. In breast cancer, overexpression of HGFR has been associated with increased tumor aggressiveness and poor prognosis.
Metastasis: HGFR activation promotes cancer cell invasion and metastasis. By enhancing cell motility, degradation of the extracellular matrix, and angiogenesis, HGFR - positive cancer cells can break away from the primary tumor, invade surrounding tissues, and enter the bloodstream or lymphatic system to spread to distant organs. In colorectal cancer, MET amplification has been linked to resistance to anti - epidermal growth factor receptor (EGFR) therapy, highlighting its role in both tumor progression and therapeutic resistance.
Cancer Stem Cells: Cancer stem cells are thought to hijack the normal stem cell ability to express HGFR. This enables them to survive, proliferate, and give rise to new cancer cells, contributing to cancer persistence and recurrence. Targeting HGFR in cancer stem cells may offer a new strategy for eliminating the root cause of cancer.
Fibrosis
In fibrotic diseases such as liver fibrosis, pulmonary fibrosis, and renal fibrosis, HGFR signaling is dysregulated. Excessive activation of HGFR contributes to tissue remodeling, fibroblast proliferation, and extracellular matrix deposition. In liver fibrosis, for example, HGFR activation in hepatic stellate cells can lead to their transformation into myofibroblasts, which are the main cells responsible for producing excessive extracellular matrix proteins, ultimately leading to liver scarring and impaired liver function.
Inflammatory Diseases
HGFR signaling also plays a role in modulating inflammatory responses and immune cell functions. In autoimmune diseases, abnormal HGFR signaling can influence the pathogenesis. For example, in rheumatoid arthritis, HGFR activation in synovial fibroblasts may contribute to the chronic inflammation and joint destruction characteristic of the disease.
Therapeutic Strategies Targeting HGFR
Small Molecule Inhibitors
Small molecule inhibitors of HGFR target the tyrosine kinase domain of the receptor, blocking its catalytic activity. Examples include crizotinib, which was initially approved for the treatment of NSCLC with anaplastic lymphoma kinase (ALK) rearrangements but also shows activity against MET - altered NSCLC. Other small molecule inhibitors in development aim to specifically target mutant or overexpressed HGFR in various cancers, with the goal of inhibiting tumor growth and metastasis.
Monoclonal Antibodies
Monoclonal antibodies can be designed to bind to different regions of HGFR or HGF, blocking ligand - receptor interaction or promoting receptor degradation. For instance, PFL - 002/VERT - 002 is a monoclonal antibody that acts as a c - MET degrader. In clinical trials, it is being evaluated for the treatment of NSCLC patients with MET variants. These antibodies can potentially disrupt the oncogenic signaling pathways activated by HGFR, offering a targeted therapy for cancer patients.
Other Therapeutic Approaches
In addition to small molecule inhibitors and monoclonal antibodies, other strategies such as RNA interference (RNAi) to knockdown HGFR expression, and gene therapy approaches to correct HGFR gene mutations are also being explored. These novel therapeutic modalities hold promise for more effective treatment of diseases associated with HGFR dysregulation.
Conclusion
The hepatocyte growth factor receptor (HGFR) is a multifunctional receptor tyrosine kinase that plays critical roles in normal physiological processes such as embryonic development, cell motility, angiogenesis, and tissue repair. However, dysregulation of HGFR signaling is strongly associated with the development and progression of various diseases, especially cancer, fibrosis, and inflammatory diseases. Understanding the structure, function, and signaling pathways of HGFR has provided valuable insights for the development of targeted therapeutic strategies. Although significant progress has been made in the development of HGFR - targeted therapies, challenges remain, such as overcoming drug resistance and improving the selectivity and efficacy of these therapies. Future research in this area is likely to focus on further elucidating the complex biology of HGFR, identifying new therapeutic targets within the HGFR signaling network, and developing more effective and personalized treatment strategies for patients with HGFR - related diseases.
Business license (three certificates in one) 